Catalog No.: PC-27489Not For Human Use, Lab Use Only.
Omzirafenib (LUT014, LUT-014) is a potent and specific, topical BRAF kinase inhibitor with IC50 of 13.3 nM and 11.7 nM for BRAF-V600E and WT BRAF respectively, paradoxically activates mitogen-activated protein kinase (MAPK).
Omzirafenib (LUT014, LUT-014) is a potent and specific, topical BRAF kinase inhibitor with IC50 of 13.3 nM and 11.7 nM for BRAF-V600E and WT BRAF respectively, paradoxically activates mitogen-activated protein kinase (MAPK).
LUT014 shows clear selectivity in vitro kinase inhibition profiling study against 59 human recombinant kinases.
inhibits proliferation of the KRASG12C-mutated human pancreatic cancer cell line MIA-PaCa-2.
LUT014 overrides the MAPK pathway inhibition, resulting in an increase in phosphorylated ERK1/2 (pERK) signaling in skin cells.
LUT014 could improve skin toxicities induced by EGFR inhibitors.
